Artwork

Content provided by Alice Watson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alice Watson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

S08 E05: ARS' Richard Lowenthal on his mission to transform allergy care

21:04
 
Share
 

Manage episode 446367171 series 3299609
Content provided by Alice Watson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alice Watson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In the latest episode of our podcast, we welcome Richard Lowenthal, CEO, ARS Pharmaceuticals, to explore the company’s mission to address unmet needs in allergy care.

During the conversation, Richard shares insights into his early career at the FDA and the regulatory challenges he faced in bringing ARS’s new nasal spray to treat severe allergic reactions to market. He also discusses the future direction of the company and much more.

A little more on EMJ GOLD’s guest…

Richard Lowenthal is the co-founder, President, and CEO, ARS Pharmaceuticals, with a leadership role since the company’s inception in 2015. Before ARS, he founded Pacific-Link Regulatory Consulting, where he contributed to the development of their diazepam nasal spray. Richard’s extensive background includes senior roles at Cadence Pharmaceuticals, Maxim Pharmaceuticals and Janssen Research Foundation, as well as work as a chemist at the FDA. He holds an M.Sc. in organic chemistry and an MSEL and has chaired the American Association of Pharmaceutical Scientists.

  continue reading

295 episodes

Artwork
iconShare
 
Manage episode 446367171 series 3299609
Content provided by Alice Watson. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Alice Watson or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

In the latest episode of our podcast, we welcome Richard Lowenthal, CEO, ARS Pharmaceuticals, to explore the company’s mission to address unmet needs in allergy care.

During the conversation, Richard shares insights into his early career at the FDA and the regulatory challenges he faced in bringing ARS’s new nasal spray to treat severe allergic reactions to market. He also discusses the future direction of the company and much more.

A little more on EMJ GOLD’s guest…

Richard Lowenthal is the co-founder, President, and CEO, ARS Pharmaceuticals, with a leadership role since the company’s inception in 2015. Before ARS, he founded Pacific-Link Regulatory Consulting, where he contributed to the development of their diazepam nasal spray. Richard’s extensive background includes senior roles at Cadence Pharmaceuticals, Maxim Pharmaceuticals and Janssen Research Foundation, as well as work as a chemist at the FDA. He holds an M.Sc. in organic chemistry and an MSEL and has chaired the American Association of Pharmaceutical Scientists.

  continue reading

295 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Listen to this show while you explore
Play